Ironwood Pharma

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ironwood Pharma excels in Q4 with LINZESS growth and pipeline advancements

Ironwood Pharmaceuticals delivered a strong performance in Q4 2022, driven by LINZESS's growth and pipeline progress. Strategic priorities emphasize profitability and portfolio strength, while challenges around pricing and data release plans require attention. Opportunities exist in expanding LINZESS sales, pediatric indications, and pipeline investments for future growth.

Ironwood Pharma excels in Q1 with LINZESS driving growth

Ironwood Pharma's Q1 2023 showcased strong LINZESS demand, revenue growth, and profitability. The company's strategic focus on LINZESS and innovative pipeline positions it well for sustained success amidst market challenges and growth opportunities.

Ironwood Pharma reports strong Q2 performance and growth opportunities

Ironwood Pharmaceuticals showcased strong performance in Q2 2023, driven by robust U.S. net sales and strategic acquisitions.
While facing challenges in managing the impact of the VectivBio acquisition on EBITDA, the company is well-positioned for growth.
Opportunities lie in expanding LINZESS sales, advancing pipeline candidates like apraglutide, and diversifying into new indications.
Overall, Ironwood's focus on maximizing key products, pipeline advancement, and financial management sets a positive trajectory.

Ironwood Pharma reports strong Q3 performance amidst strategic acquisitions

Ironwood Pharmaceuticals showcased strong performance driven by LINZESS and the acquisition of VectivBio for apraglutide.
While facing challenges in managing financial losses and addressing competitive pressures, Ironwood remains focused on growth opportunities and product development.
Opportunities lie in upcoming Phase III data for apraglutide, pediatric market expansion for LINZESS, and exploring new patient subgroups for apraglutide.

Ironwood Pharma excels in Q4, eyes pediatric market growth

Ironwood Pharmaceuticals showcased robust financial performance, strategic acquisitions, and a focus on pipeline assets during their Q4 2023 earnings call. While facing challenges in defining efficacy and pricing strategies, the company remains optimistic about growth opportunities in the GI market, particularly in the pediatric segment.

Ironwood Pharma reports Q1 growth, prepares for apraglutide launch

Ironwood Pharma's Q1 2024 performance reflects growth in LINZESS prescription volume and positive developments in its pipeline, despite challenges in net sales and guidance adjustments. The company's strategic focus on maximizing LINZESS and preparing for apraglutide's launch presents opportunities for future growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Ironwood (IRWD) delivered earnings and revenue surprises of 3.70% and 2.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2022 results and recent business performance.

Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2022 investor update conference call and webcast at 8:30 a.m.

Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call

Labcorp Holdings Inc

U.S. market indexes rose on Thursday morning as investors were encouraged by several key earnings reports and Treasury yields continued to climb.

2 Health Care Stocks That Fit Graham's Lost Formula

Today, we are revisiting Ironwood Pharmaceuticals for the first time since April of 2021. The company continues to live off its Lizness franchise and is putting its cash flow to good use in paying down debt and buying back stock.

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.

Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds

BOSTON, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced positive topline data from a Phase III clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation (FC). The trial met its primary and secondary endpoints, demonstrating that linaclotide (72 mcg) improved frequency of spontaneous bowl movements (SBM) and stool consistency. Linaclotide was generally well-tolerated, and the safety profile is consis

Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Thursday, September 8, 2022 at 8:00 a.m. ET at the Encore Boston Harbor in Everett, MA. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time t

Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference

Destination XL Group

W&T Offshore

Looking for U.S.-listed equities that have the characteristics listed below represents a solid starting point when screening the market for potential value opportunities, in my opinion:

A Trio of Stocks With High Growth Potential

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Representatives Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Matt Roache - Director of Investor Relations Conference Call Participants David Amsellem - Piper Sandler Boris Peaker - Cowen Operator Operator Good morning. My name is Stephanie, and I will be your conference operator today.

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Tom McCourt on Q2 2022 Results - Earnings Call Transcript

Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.

Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance

Ironwood (IRWD) delivered earnings and revenue surprises of -32.26% and 2.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Misses Q2 Earnings and Revenue Estimates

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its second quarter 2022 results and recent business performance. “We made progress towards our goal of becoming the leading GI healthcare company in the U.S., as the positive momentum across our business continued in the second quarter,” said Tom McCourt, chief executive officer of Ironwood. “We are pleased by the year-over-year double-digit LINZESS prescription demand growth

Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 4, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood's website at www.iro

Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented new findings during the 2022 Digestive Disease Week® (DDW) meeting that suggest colonic IW-3300 has the potential to help manage abdominopelvic visceral pain in patients with disorders of gut-brain interaction (DGBI) and related visceral pain disorders. The oral presentation, titled Colon-Targeted Delivery Of Guanylate Cyclase-C Agonist IW-3300 Relieves Comorbid Chronic Pelvic And

Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present eight studies, including two oral presentations, during the Digestive Disease Week® (DDW) 2022 meeting being held from May 21 through May 24, 2022 in San Diego, CA. One oral presentation will discuss the impact of novel guanylate cyclase-C agonist IW-3300 on comorbid chronic pelvic and somatic pain in a preclinical model of

Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Matt Roache - Director, Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Conference Call Participants Hannah Monigatti - JPMorgan David Amsellem - Piper Sandler Tim Chiang - Northland Capital Markets Boris Peaker - Cowen and Company Operator Good morning. My name is Joseph and I will be your conference operator today.

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Tom McCourt on Q1 2022 Results - Earnings Call Transcript

Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates.

Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues

Ironwood (IRWD) delivered earnings and revenue surprises of -22.22% and 2.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Q1 Earnings Miss Estimates

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its first quarter 2022 results and recent business performance. “Continuing the growth and momentum from 2021 when LINZESS exceeded $1 billion in U.S. net sales and earned blockbuster status, we believe we are in a strong position to realize our vision of becoming the leading U.S. GI healthcare company,” said Tom McCourt, chief executive officer of Ironwood. “We continue to be

Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 5, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoo

Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will be presenting at the following investor conferences: Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m. ET Barclays Global Healthcare Conference on Tuesday, March 15, 2022 at 3:20 p.m. ET A live webcast of Ironwood's presentations will be accessible through the Investors section of the company's website at www.ironwoodpharm

Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences

Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates.

News for Ironwood Pharma Stock (IRWD)